MedTrace Logo

Safety and Activity of F14 for Management of Pain Following Total Knee Replacement

NCT03541655 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-07-10

No results posted yet for this study

Summary

The safety and activity of a single, 3.5 mL dose of F14 (celecoxib) concurrent with standard of care analgesia administered following total knee replacement will be compared to standard of care analgesia alone.

Conditions

  • Total Knee Replacement
  • Postoperative Pain

Interventions

DRUG

Bupivacaine HCl

0.25% Bupivacaine HCl

DRUG

F14 (celecoxib)

Celecoxib in novel drug delivery system (BEPO™)

Sponsors & Collaborators

  • Arthritis Innovation Corporation

    lead INDUSTRY

Principal Investigators

  • Jared Foran, MD · Panorama Orthopedics & Spine Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-04
Primary Completion
2019-06-20
Completion
2020-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03541655 on ClinicalTrials.gov